• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Bicalutamide Teva 150 mg
    / Teva

    Active Ingredient
    Bicalutamide 150 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    30 X 150 mg

    not in the basket chart 80700 2488

    Related information


    One tablet per day.
    See prescribing information for full details.


    In patients with locally advanced prostate cancer (T3-T4, any N, M0; T1-T2, N+, M0), as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy.For the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.


    Females and children. Must not be given to any patient who has shown a hypersensitivity to the active substance or any of the excipients. Co-administration of terfenadine, astemizole or cisapride is contraindicated.

    Special Precautions

    Please contact distributor for full information.

    Side Effects

    Please contact distributor for full information.

    Drug interactions

    Please contact distributor for full information.

    Teva Pharmaceutical Industries Ltd, Israel